SCHEMBL2094198

SCHEMBL2094198

CO[CH]C(=O)N(c1ccc(CF)cc1)C1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 8/20 0.46
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ MITF O75030 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ PAX8 Q06710 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ENPP2 Q13822 1/20 0.41
▸ MLYCD O95822 1/20 0.41
▸ HRH3 Q9Y5N1 2/20 0.39
▸ LMNA P02545 1/20 0.37
▸ KCNH2 Q12809 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ AGTR2 P50052 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2096220 0.93 TRPM8 (0.38) TRPM8MEN1KMT2AKDM4ENPC1
SCHEMBL6003174 0.88 TRPM8 (0.43) TRPM8MEN1KMT2AKDM4ENPC1
SCHEMBL2094200 0.83 MEN1 (0.48) TRPM8MEN1KMT2AKDM4ENPC1
SCHEMBL2094924 0.79 MEN1 (0.52) TRPM8MEN1KMT2AKDM4ENPC1
SCHEMBL2094921 0.79 MEN1 (0.52) TRPM8MEN1KMT2AKDM4ENPC1
SCHEMBL6003176 0.79 MEN1 (0.47) TRPM8MEN1KMT2AKDM4ENPC1
SCHEMBL2094195 0.77 MEN1 (0.48) TRPM8MEN1KMT2AKDM4ENPC1
SCHEMBL2096223 0.75 OPRM1 (0.41) TRPM8MEN1KMT2AKDM4ENPC1
SCHEMBL2097748 0.71 MEN1 (0.42) MEN1KMT2AKDM4ENPC1MITF
SCHEMBL2097750 0.71 MEN1 (0.42) MEN1KMT2AKDM4ENPC1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 — — US disclosed
CN-100497345-C 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2009-06-10 — — CN disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 — — EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 — — US disclosed
CN-1878777-A 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2006-12-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 TRPM8 4001/4885MEN1 4525/4885KMT2A 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback